Skip to Main Content

OVERVIEW

On December 31, 2019, public health authorities in Wuhan, China, reported a cluster of cases of severe atypical pneumonia. Over the next 2 months, experts identified and sequenced the Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) as the virus responsible, and Coronavirus Disease 2019 (COVID-19) spread across the world, reaching pandemic status.1 COVID-19 was responsible for more than 1.8 million deaths worldwide in 2020, and it was one of the leading causes of death in the United States.2,3  Public health authorities recommended social distancing, widespread testing, travel bans, stay-at-home orders, mask mandates, and restricted commerce to slow the spread of the infection.

PATHOPHYSIOLOGY

SARS-CoV-2 is an enveloped RNA β-coronavirus genetically similar to the virus that causes Severe Acute Respiratory Distress Syndrome (SARS). SARS-CoV-2 has four structural proteins (spike, membrane, envelope, and nucleocapsid) and binds principally to the angiotensin-converting enzyme 2 (ACE2) receptor, which is widely expressed in the lung and elsewhere.4 SARS-CoV-2 is transmitted between humans primarily through respiratory droplets (large droplets of secretions that can propagate from an infected individual) and close personal contact. The incubation period of COVID-19 is 2–7 days (median 5), and viral shedding occurs up to 7 days prior to the onset of symptoms with maximal production in the first week after symptom onset (Figure 154b-1).5-8

FIGURE 154b-1

Time course of SARS-CoV-2 infection. Approximately 5 days after the initial exposure, patients develop symptoms, but viral shedding often occurs before symptoms. Viral replication peaks in the first week of infection, with severe illness manifesting during the second week.

(Reproduced with permission from Cevik M, Kuppalli K, Kindrachuk J, et al: Virology, transmission, and pathogenesis of SARS-CoV-2, BMJ 2020 Oct 23;371:m3862. 7

Data from Oberfeld B, Achanta A, Carpenter K, et al: SnapShot: COVID-19, Cell 2020 May 14;181(4):954-954.e1 and McGrath BA, Brenner MJ, Warrillow SJ, et al: Tracheostomy in the COVID-19 era: global and multidisciplinary guidance, Lancet Respir Med 2020 Jul;8(7):717-725.)

COVID-19 severity of illness varies. Estimates are 1 in 5 of those infected with SARS-CoV-2 have no or minimal symptoms, yet asymptomatic infected individuals still shed virus and may trigger up to 60% of COVID-19 transmission.9,10 An estimated 15% of infected patients develop severe disease, which can progress to a profound inflammatory lung injury consistent with acute respiratory distress syndrome (ARDS).11 In severe COVID-19, features include overwhelming systemic inflammation, hypercoagulability, septic shock, and multisystem organ failure.

CLINICAL PRESENTATION

Most symptomatic COVID-19 patients present initially with mild disease, with fever or fever history (78%), cough (57%), and shortness of breath (23%) being the most common symptoms. Fatigue (31%), myalgia (17%), and headache (13%) also are common (Table 154b-1).12 Loss of smell (anosmia) or taste (ageusia) are symptoms that ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.